Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12 .

Baetz T, Chen BE, Couban S, Tom Kouroukis C, Buckstein R, Kuruvilla J, Howson-Jan K, Szwajcer D, Federico M, Meyer RM, Djurfeldt MS, Hay AE, Shepherd L, Crump M.

Leuk Lymphoma. 2016 Jun 7:1-6. [Epub ahead of print]

PMID:
27266754
2.

Safety and feasibility of red cell exchange for sickle cell disease across Canada.

Ward R, Barth D, Couban S, Naessens V, Ritchie B, Yenson P, Kuo K.

Transfus Apher Sci. 2016 May 6. pii: S1473-0502(16)30023-4. doi: 10.1016/j.transci.2016.05.004. [Epub ahead of print]

PMID:
27179925
3.

Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.

Couban S, Aljurf M, Lachance S, Walker I, Toze C, Rubinger M, Lipton JH, Lee SJ, Szer R, Doocey R, Lewis ID, Huebsch L, Howson-Jan K, Lalancette M, Almohareb F, Chaudhri N, Ivison S, Broady R, Levings M, Fairclough D, Devins G, Szwajcer D, Foley R, Smith C, Panzarella T, Kerr H, Kariminia A, Schultz KR.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1410-5. doi: 10.1016/j.bbmt.2016.04.017. Epub 2016 May 3.

PMID:
27154847
4.

Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.

Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM.

Br J Haematol. 2016 Apr 13. doi: 10.1111/bjh.14100. [Epub ahead of print]

PMID:
27072903
5.

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.

Kariminia A, Holtan SG, Ivison S, Rozmus J, Hebert MJ, Martin PJ, Lee SJ, Wolff D, Subrt P, Abdossamadi S, Sung S, Storek J, Levings M, Aljurf M, Arora M, Cutler C, Gallagher G, Kuruvilla J, Lipton J, Nevill TJ, Newell LF, Panzarella T, Pidala J, Popradi G, Szwajcer D, Tay J, Toze CL, Walker I, Couban S, Storer BE, Schultz KR.

Blood. 2016 Jun 16;127(24):3082-91. doi: 10.1182/blood-2015-09-668251. Epub 2016 Mar 28.

PMID:
27020088
6.

Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study.

Michelis FV, Atenafu EG, Couban S, Frazer J, Shivakumar S, Hogge DE, Toze CL, Rajkhan W, Kim HJ, Daly A, Slaby J, Finke J, Kiss T, Bredeson C, Sabloff M, Sheppard D, Bakkar M, Brune M, Wall DA, Paulson K, Popradi G, Walker I, Messner HA.

Bone Marrow Transplant. 2016 Jul;51(7):1019-21. doi: 10.1038/bmt.2016.60. Epub 2016 Mar 14. No abstract available.

PMID:
26974273
7.

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.

Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R; Canadian Blood and Marrow Transplant Group.

Lancet Oncol. 2016 Feb;17(2):164-73. doi: 10.1016/S1470-2045(15)00462-3. Epub 2015 Dec 24.

PMID:
26723083
8.

Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.

Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ; Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium.

Am J Hematol. 2016 Mar;91(3):322-9. doi: 10.1002/ajh.24285.

PMID:
26701142
9.

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.

Kuruvilla J, MacDonald DA, Kouroukis CT, Cheung M, Olney HJ, Turner AR, Anglin P, Seftel M, Ismail WS, Luminari S, Couban S, Baetz T, Meyer RM, Hay AE, Shepherd L, Djurfeldt MS, Alamoudi S, Chen BE, Crump M.

Blood. 2015 Aug 6;126(6):733-8. doi: 10.1182/blood-2015-01-622084. Epub 2015 Jun 24.

PMID:
26109202
10.

Screening for Occult Cancer in Unprovoked Venous Thromboembolism.

Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, Routhier N, Douketis J, Danovitch K, Lee AY, Le Gal G, Wells PS, Corsi DJ, Ramsay T, Coyle D, Chagnon I, Kassam Z, Tao H, Rodger MA; SOME Investigators.

N Engl J Med. 2015 Aug 20;373(8):697-704. doi: 10.1056/NEJMoa1506623. Epub 2015 Jun 22.

11.

G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept.

Deotare U, Al-Dawsari G, Couban S, Lipton JH.

Bone Marrow Transplant. 2015 Sep;50(9):1150-6. doi: 10.1038/bmt.2015.80. Epub 2015 Apr 27. Review.

PMID:
25915812
12.

Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.

Cheung MC, Hay AE, Crump M, Imrie KR, Song Y, Hassan S, Risebrough N, Sussman J, Couban S, MacDonald D, Kukreti V, Kouroukis CT, Baetz T, Szwajcer D, Desjardins P, Shepherd L, Meyer RM, Le A, Chen BE, Mittmann N; Committee on Economic Analysis and the Hematology Disease Site Committee, NCIC Clinical Trials Group.

J Natl Cancer Inst. 2015 Apr 13;107(7). pii: djv106. doi: 10.1093/jnci/djv106. Print 2015 Jul.

13.

The Canadian Choosing Wisely campaign: the Canadian Hematology Society's top five tests and treatments.

Hillis CM, Schimmer AD, Couban S, Crowther MA.

Ann Hematol. 2015 Apr;94(4):541-5. doi: 10.1007/s00277-015-2304-4. Epub 2015 Feb 1. Review.

PMID:
25637447
14.

A prospective cohort study of the feasibility and efficacy of iron reduction by phlebotomy in recipients of hematopoietic SCT.

Kew AK, Clarke S, Ridler A, Burrell S, Edwards JA, Doucette S, Couban S.

Bone Marrow Transplant. 2015 Mar;50(3):457-8. doi: 10.1038/bmt.2014.273. Epub 2014 Dec 15. No abstract available.

PMID:
25501351
15.

Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.

Lachaine J, Mathurin K, Barakat S, Couban S.

Eur J Haematol. 2015 Sep;95(3):218-29. doi: 10.1111/ejh.12475. Epub 2015 Feb 4.

PMID:
25354894
16.

A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults.

Seftel MD, Barnett MJ, Couban S, Leber B, Storring J, Assaily W, Fuerth B, Christofides A, Schuh AC.

Curr Oncol. 2014 Oct;21(5):234-50. doi: 10.3747/co.21.2183.

17.

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.

Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE.

J Clin Oncol. 2014 Nov 1;32(31):3490-6. doi: 10.1200/JCO.2013.53.9593. Epub 2014 Sep 29.

18.

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.

DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM.

Leukemia. 2015 Mar;29(3):526-34. doi: 10.1038/leu.2014.229. Epub 2014 Jul 31.

19.

Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experience.

AlJohani NI, Thompson K, Hasegawa W, White D, Kew A, Couban S.

Curr Oncol. 2014 Jun;21(3):e434-40. doi: 10.3747/co.21.1846.

20.

Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.

Couban S, Savoie L, Mourad YA, Leber B, Minden M, Turner R, Palada V, Shehata N, Christofides A, Lachance S.

Curr Oncol. 2014 Apr;21(2):e265-309. doi: 10.3747/co.21.1834.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk